David Dsouza is a distinguished Principal Scientist at Catalent Pharma Solutions, where he plays a pivotal role in advancing the field of biopharmaceutical development. With a robust background in vaccine development, gene therapy, and mammalian cell culture, David has consistently demonstrated his expertise in bioprocess...
David Dsouza is a distinguished Principal Scientist at Catalent Pharma Solutions, where he plays a pivotal role in advancing the field of biopharmaceutical development. With a robust background in vaccine development, gene therapy, and mammalian cell culture, David has consistently demonstrated his expertise in bioprocess development, managing the entire lifecycle of bioprocesses from initial scaling strategies to the refinement of formulations. His leadership extends to guiding a dedicated team of four scientists, where he fosters a collaborative environment that encourages innovation and efficiency.
In his current role, David is instrumental in driving the development of novel biologics from pre-clinical Phase I through Phase II, contributing to over 25 client projects that span various therapeutic areas. His specialization in upstream process development is complemented by his hands-on experience in scaling up manufacturing technologies, overseeing operations that reach up to 2000 L. David’s proficiency in critical techniques such as cell biology, confocal microscopy, molecular cloning, and protein purification enables him to tackle complex challenges in bioprocess optimization.
David's commitment to innovation is evident in his ability to refine processes that enhance productivity and reduce costs, ensuring that Catalent remains at the forefront of biopharmaceutical advancements. His expertise in techniques like qPCR, RT-PCR, and flow cytometry further solidifies his role as a key contributor to the success of the projects he oversees. As he continues to lead cross-functional teams, David Dsouza exemplifies the integration of scientific rigor and strategic leadership in the ever-evolving landscape of biopharmaceutical development.
